Clinical Trials

Clinical Trial Detail

Return to search results.

PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma (PD-1)

Complete title: An Exploratory Study of the Biologic Effects of Nivolumab and Nivolumab in Combination with Ipilimumab Treatment in Subjects with Advanced Melanoma (Unresectable or Metastatic)

Research Study Number       20122036
    
Principal Investigator       Shailender Bhatia, MD
    
Phase       I

Look up trial at NIH

Research Study Description

The purpose of this study is to evaluate pharmacodynamic changes of Nivolumab and Nivolumab in combination with Ipilimumab treatment on the biomarkers measured in the peripheral blood and tumor tissues of subjects with advanced melanoma (unresectable or advanced)

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.



Research Study Number       20122036
    
Contact       Nichole Pelz
    
Telephone       206/288-7476
    
   

Keywords
Melanoma; Solid Tumors; Neoplasms, Germ Cell and Embryonal; Neuroendocrine Tumor; Neoplasms; Neuroectodermal Tumors; Neoplasms, Nerve Tissue

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials